This study presents the development and preclinical characterization of a novel class of PSMA-targeting hybrid molecules based on the theranostic radiopharmaceutical PSMA-617 for pre- and intraoperative detection of prostate cancer. Here, FOLH1 is linked to prostate carcinoma.